Critical appraisal of paroxetine for the treatment of vasomotor symptoms

References

• GoldEBThe timing of the age at which natural menopause occursObstet Gynecol Clin North Am201138342544021961711
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and GynecologistsPractice Bulletin No 141: management of menopausal symptomsObstet Gynecol201412320221624463691
   PubMed Web of Science ®Google Scholar
• GoodmanNFCobinRHGinzburgSBKatzIAWoodeDEAmerican Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopauseEndocr Pract201117suppl 612522193047
   PubMed Web of Science ®Google Scholar
• ArcherDFSturdeeDWBaberRMenopausal hot flushes and night sweats: where are we nowClimacteric201114551552821848495
   PubMed Web of Science ®Google Scholar
• North American Menopause SocietyThe 2012 hormone therapy position statement of The North American Menopause SocietyMenopause201219325727122367731
   PubMed Web of Science ®Google Scholar
• de VilliersTJGassMLHainesCJGlobal consensus statement on menopausal hormone therapyMaturitas201374439139223497918
   PubMed Web of Science ®Google Scholar
• de VilliersTJPinesAPanayNUpdated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife healthClimacteric201316331633723672656
   PubMed Web of Science ®Google Scholar
• MaclennanAHBroadbentJLLesterSMooreVOral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushesCochrane Database Syst Rev20044CD00297815495039
   PubMedGoogle Scholar
• ModenaMGSismondiPMueckAORisks and benefits of estrogen plus progestin in healthy menopausal women: principle results from the Women’s Health Initiative randomized controlled trialJAMA200228832133312117397
   PubMed Web of Science ®Google Scholar
• SimonJAPortmanDJKaunitzAMLow-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trialsMenopause201320101027103524045678
   PubMed Web of Science ®Google Scholar
• StearnsVBeebeeKLIyengarMDubeEParoxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trialJAMA20032892827283412783913
   PubMed Web of Science ®Google Scholar
• SoaresCNJoffeHVigueraACParoxetine versus placebo for women in midlife after hormone discontinuationAm J Med200812115916218261506
   PubMed Web of Science ®Google Scholar
• StearnsVIsaacsCRowlandJA pilot trial assessing the efficacy of paroxetine hydrocholoride (Paxil) in controlling hot flashes in breast cancer survivorsAnn Oncol200011172210690382
   PubMed Web of Science ®Google Scholar
• WeitznerMAMoncelloJJacobsenPBMintonSA pilot trial of paroxetine for the treatment of the hot flashes and associated symptoms in women with breast cancerJ Pain Symptom Manage200223433734511997203
   PubMed Web of Science ®Google Scholar
• StearnsVSlackRGreepNParoxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trialJ Clin Oncol200523286919693016192581
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Advisory Committee for Reproductive Health DrugsParoxetine Mesylate for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause [updated March 4, 2013]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM343175.pdfAccessed October 24, 2014
   Google Scholar
• CatelliMBhaskarSLippmanJPharmacokinetic properties of once-daily oral low-dose mesylate salt of paroxetine (LDMP 7.5 mg) following single and multiple doses in healthy postmenopausal womenClin Ther201335686286923795577
   PubMed Web of Science ®Google Scholar
• CubedduAGianniniABucciFParoxetine increased brain derived neurotrophic factor in menopausal womenMenopause201017233834319934779
   PubMed Web of Science ®Google Scholar
• YasuiTYamadaMUemuraHChanges in circulating cytokine levels in midlife women with psychological symptoms with selective serotonin reuptake inhibitor and Japanese traditional medicineMaturitas200962214615219179025
   PubMed Web of Science ®Google Scholar
• UshiroyamaTIkedaAUekiMEvaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transitionJ Med2004351–615116218084873
   PubMedGoogle Scholar
• Nolvadex (tamoxifen citrate) [package insert]Wilmington, DelawareAstraZeneca Pharmaceuticals LP [updated August, 2004]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/17970s053lbl.pdfAccessed February 6, 2015
   Google Scholar
• National Comprehensive Cancer NetworkBreast cancer (Version 3.2014) [updated 2014]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdfAccessed October 29, 2014
   Google Scholar
• BursteinHJTeminSAndersonHAdjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused updateJ Clin Oncol201432212255226924868023
   PubMed Web of Science ®Google Scholar
• VisvanathanKHurleyPBantugEUse of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guidelineJ Clin Oncol201331232942296223835710
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care ExcellenceAdvanced breast cancer, diagnosis and treatment [updated 2014]. Available from: http://www.nice.org.uk/guidance/cg81/resources/guidance-advanced-breast-cancer-update-pdfAccessed December 29, 2014
   Google Scholar
• National Institute for Health and Care ExcellenceEarly and locally advanced breast cancer, diagnosis and treatment [updated 2014]. Available from: http://www.nice.org.uk/guidance/cg80/resources/guidance-early-and-locally-advanced-breast-cancer-pdfAccessed December 29, 2014
   Google Scholar
• StearnsVJohnsonMDRaeJMActive tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetineJ Natl Cancer Inst200395231758176414652237
   PubMed Web of Science ®Google Scholar
• JinYDestaZStearnsVCYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatmentJ Natl Cancer Inst2005971303915632378
   PubMed Web of Science ®Google Scholar
• KellyCMJuurlinkDNGomesTSelective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort studyBMJ2010340c69320142325
   PubMed Web of Science ®Google Scholar
• American Society of Clinical OncologyAdjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update Data supplement [updated 2014]. Available from: http://www.instituteforquality.org/sites/instituteforquality.org/files/adju_endo_upd_data_supplement_2014_0.pdfAccessed December 29, 2014
   Google Scholar
• PinkertonJVJoffeHKazenpourKMekonnenHBhaskarSLippmanJLow-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopauseMenopause2015221505825137243
   PubMed Web of Science ®Google Scholar
• PortmanDJKaunitzAMKazempourKMekonnenHBhaskarSLippmanJEffects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopauseMenopause201421101082109024552977
   PubMed Web of Science ®Google Scholar
• JoffeHVDivision Director’s Summary Review for Approval of Brisdelle (paroxetine mesylate) [updated June 28, 2013]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204516Orig1s000SumR.pdfAccessed March 19, 2015
   Google Scholar
• ParoxetineRED BOOK [AUHSOP intranet database]Greenwood Village, COTruven Health Analytics [updated daily]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/9F9DDB/ND_App-Product/evidencexpert/DUPLICATIONSHIELDSYNC/49D885/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/redbook.FindRedBook?navitem=topRedBookAccessed December 14, 2014
   Google Scholar
• PaxilCR(paroxetine hydrochloride) controlled release tablets [package insert]Mississauga, ONGlaxoSmithKline Inc [updated March, 2014]. Available from: http://www.gsk.ca/english/docs-pdf/product-monographs/Paxil-CR.pdfAccessed October 24, 2014
   Google Scholar